Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer
This patient-level real-world analysis demonstrated very strong, positive correlations between iDFS and OS, supporting the use of iDFS as a reliable primary end point in adjuvant HR+/HER2- EBC.
Authors
- Murat Akdere (ORCID: https://orcid.org/0009-0001-4883-0463)
- Pedram Razavi (ORCID: https://orcid.org/0000-0003-4236-0576)
- Rishi Rajat Adhikary
- Ilia Ferrusi (ORCID: https://orcid.org/0000-0002-9177-9683)
- Andriy Danyliv (ORCID: https://orcid.org/0000-0003-3382-5976)
- Stephanie L. Graff (ORCID: https://orcid.org/0000-0003-1928-1722)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Joyce O’Shaughnessy (ORCID: https://orcid.org/0000-0001-6764-2807)
- Lee S. Schwartzberg (ORCID: https://orcid.org/0000-0002-7433-3428)
- Lowell L. Hart
- Wolfgang Janni
Institutions
- Novartis (Switzerland) (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Brown University (US)
- Texas Oncology (US)
- Baylor University Medical Center (US)
- Renown Health (US)
- Novartis (India) (IN)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- Novartis (United States) (US)
- Florida Cancer Specialists & Research Institute (US)
- University Hospital Ulm (DE)
- Wake Forest University (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1002/cncr.35817
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Novartis Pharmaceuticals Corporation